Review of Medications Used in the Treatment of Diabetes Mellitus

Abstract

Objective:

To review the pathophysiology of diabetes mellitus and outline currently available medications used in its treatment.

Data Sources:

A MEDLINE/PubMed search (1966-December 2009) was conducted for English-language articles using the terms diabetes mellitus, pharmacotherapy, metformin, thiazolidinedione, sulfonylurea, meglitinide, α-glucosidase inhibitor, DPP-4 inhibitor, colesevelam, bromocriptine, exenatide, pramlintide, and insulin. Book chapters relevant to the pathophysiology and pharmacologic treatment of diabetes were also searched.

Study Selection and Data Extraction:

Articles and chapters pertinent to the pharmacologic management of diabetes mellitus were reviewed.

Data Synthesis:

Type 1 diabetes is characterized by an absolute lack of insulin production by the β-cells of the pancreas, requiring insulin therapy. Type 2 diabetes is characterized by both insulin resistance and a relative or absolute lack of insulin secretion. Because type 2 diabetes involves both insulin resistance and decreased insulin production over time, people with type 2 diabetes can be treated with a variety of drugs currently on the market. Therapies currently on the market include metformin, thiazolidinediones, sulfonylureas, meglitinides, α-glucosidase inhibitors, DPP-4 inhibitors, colesevelam, bromocriptine, exenatide, pramlintide, and insulin.

Conclusions:

Given the multitude of medications available for the treatment of diabetes, it is important that pharmacy technicians and pharmacists be aware of the various agents currently on the market. With a solid foundation of knowledge regarding diabetes medications, a huge impact can be made on the quality of care of the customers and patients the pharmacy serves.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. http://cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf (accessed 2009 Oct 2).

American Diabetes Association. All about diabetes. 2009. http://www.diabetes.org/about-diabetes.jsp (accessed 2009 Oct 27).

Talbert

. Diabetes mellitus. In: DiPiro

Talbert

Yee

Matzke

Wells

Posey

, eds. Pharmacotherapy: a patho-physiologic approach. 7th ed. New York: McGraw-Hill, 2008: 1205–41.

Brunton

Lazo

Parker

. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006: 1613–45.

Bailey

Path

MRC

Turner

. Drug therapy: Metformin. N Engl J Med 1996; 334: 574–9.

DeFronzo

. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia 1992; 35: 389–97.

Dornhorst

. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709–16.

Bailey

. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005; 7: 675–91.

Clinical Pharmacology Online. http://clinicalpharmacology.com (accessed 2009 Nov 13).

10.

Krentz

Bailey

. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005; 65: 385–411.

11.

Sibal

Home

. Management of type 2 diabetes: NICE guidelines. Clin Med 2009; 9: 353–7.

12.

Package insert. Glucophage (metformin hydrochloride). Princeton, NJ: Bristol-Myers Squibb Company, January 2009.

13.

Setter

Iltz

Thams

Campbell

. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin Ther 2003; 25: 2991–3026.

14.

McCarren

. Type 2 drugs. Diabetes Forecast 2008:RG7–9.

15.

Holst

Gromada

. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199–E206.

16.

Neumiller

Odegard

White

Setter

Campbell

. Looking to the future: Focus on DPP-IV inhibitors for the treatment of type 2 diabetes and emerging therapies. Diabetes Educ 2008; 34: 183–200.

17.

Sonnett

Levien

Neumiller

Gates

Setter

. Cole-sevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31: 245–59.

18.

Package insert. Welchol. (colesevelam hydrochloride). Parsippany, NJ: Daiichi Sankyo, Inc, October 2009.

19.

Bays

Cohen

. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23: 1673–84.

20.

Garg

Grundy

. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416–22.

21.

Thomson

Keelan

. Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion 1987; 38: 160–70.

22.

Package insert. Cycloset (bromocriptine). Tiverton, RI: Veroscience, April 2009.

23.

Hester

. Cycloset: A new bromocriptine formulation for diabetes. Pharmacist's Letter/Prescriber's Letter 2009; 25: 250878.

24.

Pijl

Ohashi

Matsuda

Miyazaki

Mahankali

Kumar

. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154–61.

25.

Bailey

. Metformin: A multitasking medication. Diab Vasc Dis Res 2008; 5: 156.

26.

Bailey

Day

. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009; 11: 527–33.

27.

Dailey

Kim

Lian

. Patient compliance and persistence with anti-hyperglycemic therapy: Evaluation of a population of type 2 diabetic patients. J Int Med Res 2002; 30: 71–9.

28.

Vanderpoel

Hussein

Watson-Heidari

Perry

. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clin Ther 2004; 26: 2066–75.

29.

Barnett

. Exenatide. Expert Opin Pharmacother 2007; 8: 2539–608.

30.

Package insert. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., October 2009.

31.

Odegard

Setter

Iltz

. Update in the pharmacologic treatment of diabetes mellitus: Focus on pramlintide and exenatide. The Diabetes Educator 2006; 32: 693–712.

32.

Linnebjerg

Kothare

Park

. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–27.

33.

Food and Drug Administration. Byetta label revised to include safety information on possible kidney problems. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188708.htm (accessed 2009 Dec 29).

34.

Bain

Stephens

. Exenatide and pancreatitis: An update. Expert Opin Drug Saf 2008; 7: 643–4.

35.

Package insert. Symlin (pramlintide acetate). San Diego, CA: Amylin Pharmaceuticals, Inc., July 2008.

36.

Neumiller

Odegard

Wysham

. Update on insulin management in type 2 diabetes mellitus. Diabetes Spectrum 2009; 22: 85–91.